v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 35,087 $ 25,841
Short-term investments 11,152 25,884
Restricted cash 146 146
Accounts receivable 35,834 34,108
Inventories 16,084 9,706
Other current assets 8,131 6,184
Total current assets 106,434 101,869
Property and equipment, net 2,989 3,856
Operating lease assets 51,981 54,935
Other assets 3,868 4,844
Total assets 165,272 165,504
Current liabilities:    
Accounts payable 2,854 3,684
Accrued compensation 5,707 11,519
Accrued research and development expenses 15,928 17,364
Deferred revenue 123,154 77,833
Other current liabilities 33,047 31,826
Total current liabilities 180,690 142,226
Deferred revenue - long-term 719 37,562
Operating lease liabilities - long-term 42,197 45,693
Liability related to the sale of future revenues - long-term 35,573 34,623
Other long-term liabilities 4,401 4,631
Total liabilities 263,580 264,735
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):    
Common stock - $0.0001 par value, 500,000 shares authorized as of March 31, 2024 and December 31, 2023; 120,325 and 106,447 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 12 11
Additional paid-in capital 1,902,637 1,870,112
Accumulated other comprehensive (loss) income (55) (204)
Accumulated deficit (2,000,902) (1,969,150)
Total stockholders' equity (deficit) (98,308) (99,231)
Total liabilities and stockholders' equity (deficit) $ 165,272 $ 165,504

Source

10-Q
HTML PDF
XBRL
ZIP